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OBJECTIVE
To investigate the efficacy, safety, and tolerability of oral semaglutide added to
insulin with or without metformin.
RESEARCH DESIGN AND METHODS
Patients with type 2 diabetes uncontrolled on insulin with or without metformin
were randomized to oral semaglutide 3mg (N5 184), 7mg (N5 182), or 14mg (N5
181) or to placebo (N5 184) in a 52-week, double-blind trial. End points were change
from baseline to week 26 in HbA1c (primary) and body weight (confirmatory
secondary). Two estimands were defined: treatment policy (effect regardless of trial
product discontinuation or rescue medication) and trial product (effect assuming
trial product continuation without rescue medication) in randomized patients.
RESULTS
Oral semaglutide was superior to placebo in reducing HbA1c (estimated treatment
difference [ETD] –0.5% [95%CI –0.7, –0.3], –0.9% [–1.1, –0.7], and –1.2% [–1.4, –1.0]
for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD 20.9 kg [95% CI
21.8,20.0],22.0 kg [23.0,21.0], and23.3 kg [24.2,22.3]; P5 0.0392 for 3mg, P£
0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater
dose-dependent HbA1c and body weight reductions versus placebo were achieved
with oral semaglutide at weeks 26 and 52 (both estimands). The most fre-
quent adverse event with oral semaglutide was nausea (11.4–23.2% of patients
vs. 7.1% with placebo; mostly mild to moderate).
CONCLUSIONS
Oral semaglutide was superior to placebo in reducing HbA1c and bodyweight when
added to insulin with or without metformin in patients with type 2 diabetes. The
safety profile was consistent with other glucagon-like peptide 1 receptor agonists.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce HbA1c with a low risk of
hypoglycemia and favorable effects on body weight (1,2). Furthermore, some GLP-
1RAs provide cardiovascular benefits and are recommended by diabetes and
cardiology guidelines for patients with concomitant cardiovascular disease (3,4).
Combined with insulin, GLP-1RAs reduce HbA1c and body weight from baseline
without increasing hypoglycemia (5–9). Semaglutide is a GLP-1RA, and its
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subcutaneous, once-weekly formulation
improved glycemic control and reduced
body weight from baseline when used
alongside basal insulin in patients with
type 2 diabetes (6).
An oral formulation of semaglutide
has been developed and is the first oral
GLP-1RA to enter phase 3 trials. As
peptides have low oral bioavailability,
oral semaglutide is coformulated with
the absorption enhancer sodiumN-(8-[2-
hydroxybenzoyl] amino) caprylate,which
facilitates semaglutide absorption across
the gastric mucosa (10).
This article reports the findings of the
Peptide Innovation for Early Diabetes
Treatment 8 (PIONEER 8) trial, which
investigated the efficacy, safety, and tol-
erability of oral semaglutide added onto
insulin (basal, basal-bolus, or premixed)
with or without metformin in patients
with uncontrolled type 2 diabetes.
RESEARCH DESIGN AND METHODS
Trial Design
This randomized, double-blind, placebo-
controlled, parallel-group trial was con-
ducted at 111 sites in nine countries
(Supplementary Appendix 1) between
2 February 2017 and 18 January 2018
(NCT03021187). There was a 2-week
screening period, 52-week treatment
period, and 5-week follow-up period
(Supplementary Fig. 1A).
Patients were randomized 1:1:1:1 to
once-daily oral semaglutide 3, 7, or 14mg
or placebo using an interactive web re-
sponse system (Supplementary Appendix
2). Randomization was stratified by pa-
tients’ country of origin (Japanese or
non-Japanese) and background treatment
(metformin or no metformin; basal, basal-
bolus, or premixed insulin).
A 20% reduction in total daily insu-
lin dosage was recommended at ran-
domization and maintained to week 8
(Supplementary Fig. 1B) unless an in-
crease was required to prevent acute
metabolic deterioration. The treatment
period was then split into two stages
defined by restrictions in total daily in-
sulin dosage. It could be altered during
weeks 8–26, without exceeding the pre-
randomization dosage, and was freely
adjustable at the investigator’s discretion
during weeks 26–52. Throughout the
trial, the total daily insulin dosage could be
reduced as needed. Itwas recommended
that adjustments were made based on
the lowest of three self-measured blood
glucose (SMBG) values, preferably mea-
sured on 3 consecutive days prior to
each phone contact/site visit, with the
aim of obtaining a fasting plasma glucose
(FPG) concentration of 4.0–5.5 mmol/L
(71–99 mg/dL) and HbA1c ,7.0% (53
mmol/mol) (Supplementary Appendix
3). In brief, dosage was increased in
increments of 2unitsbasedonFPGvalues,
starting at 2 units for 5.6–7.0 mmol/L
(100–126 mg/dL), up to 8 units if .9.0
mmol/L (.162 mg/dL). For patients on
basal-bolus insulin takenmore than once
daily, it was recommended to titrate
each dose separately. For patients on basal-
bolus insulin, recommendations were
provided only for the basal component.
The trial protocol was approved by the
institutional review board/independent
ethics committee at each site, and the
trial was conducted in accordance with
International Council on Harmonization
(ICH) Good Clinical Practice guidelines
and the Declaration of Helsinki. All
patients provided written informed
consent.
Two different scientific questions re-
lated to the efficacy objectives were ad-
dressed through the definition of two
estimands: the treatment policy estimand
and the trial product estimand. Both
estimands were defined based on inter-
actions with regulatory agencies (11).
The treatment policy estimand ad-
dressed the question of the treatment
effect for all randomized patients regard-
less of trial product discontinuation or use
of rescue medication. This estimand re-
flects the intention-to-treat principle as
defined in ICH E9 (12). This estimand
reflects the effect of initiating treatment
with oral semaglutide compared with
initiating treatment with placebo, both
potentially followed by either discontinu-
ation of trial product and/or addition of, or
switch to, another glucose-lowering drug.
The trial product estimand addressed
the question of the treatment effect for
all randomized patients under the as-
sumption that all patients remained on
trial product for the entire planned du-
ration of the trial and did not use rescue
medication. This estimand aims at re-
flecting the effect of oral semaglutide
compared with placebo without the con-
founding effect of rescue medication.
The statistical analysis that was applied
to estimate this estimand is similar to
that used in the majority of previously
published phase 3a diabetes trials (13).
Trial product discontinuation and initi-
ation of rescue medication were ac-
counted for by the treatment policy
strategy for the treatment policy estimand,
and by the hypothetical strategy for the
trial product estimand, as defined in draft
ICH E9 (R1) (14). Further details are pro-
vided in Supplementary Appendix 4.
Patient Population
Adult patients with type 2 diabetes
diagnosed $90 days before screening
with baseline HbA1c 7.0–9.5% (53–80
mmol/mol) were enrolled. Patients were
required to be on a stable regimen of
basal, basal-bolus (in any combination),
or premixed insulin (including combina-
tions of soluble insulin) at$10 units/day
for $90 days before screening. If used,
concomitant metformin was required to
be at a stable dosage ($1,500mg daily or
the maximum tolerated dosage) for
$90 days before screening. Aside
from metformin, the insulin regimens
described above, or short-term (#14 days)
changes in insulin dosage for acute
illness, use of any other glucose-lowering
medication was not allowed in the 90
days before screening. Full eligibility
criteria are provided in Supplementary
Table 1.
Drug Administration
As the presence of food or liquid in the
stomach impairs absorption of oral
semaglutide (10), patients were instructed
to administer trial product in the morning
in a fasting state with#120mL (#4 fl oz)
water, then towait at least 30min before
the first meal of the day or taking other
oral medication. Tablets were not to
be broken or chewed. These instructions
were to ensure sufficient absorption of
oral semaglutide. Patients randomized to
oral semaglutide 3mgwere initiated and
remained on the 3-mg dose. Those ran-
domized to 7 and14mgbegan treatment
at 3 mg, and the dose was escalated to
7 mg after 4 weeks and to 14 mg after a
further 4 weeks until the randomized
dose was achieved. Patients and inves-




or intensification of existing medication)
was available to patients taking trial
product who had persistent or unac-
ceptable hyperglycemia based on pre-
defined FPG and HbA1c rescue criteria
(two measures of FPG .11.1 mmol/L
[.200 mg/dL] from week 16 onward
and/or HbA1c .8.5% [.69.4 mmol/mol]
from week 26 onward). Intensification
was defined as a .20% increase in
the dose of existing medication from
baseline, maintained for either two or
more visits (for insulin) or$21 days (for
other medications). Upon trial product
discontinuation (either prematurely or at
the end of the treatment period at week
52), patients had their total daily insulin
dosage adjusted and/or switched to a
suitable marketed product at the inves-
tigators’ discretion. The use of GLP-1RAs
was prohibited until after the follow-up
visit, 5 weeks after the last dose of trial
product. Patients continued in the trial
after receiving rescue medication or pre-
maturely discontinuing trial product.
Study End Points and Assessments
The primary end point was change in
HbA1c, and the confirmatory secondary
end point was change in body weight,
both from baseline to week 26.
Supportive secondary end points, as-
sessed at weeks 26 and 52, were: changes
from baseline in HbA1c (week 52 only),
body weight (week 52 only), total daily
insulindosage, FPG,SMBG7-pointprofile
(mean and mean postprandial incre-
ment), BMI, waist circumference, and
fasting lipid profile; whether patients
achieved HbA1c ,7.0% (53 mmol/mol)
and#6.5% (48 mmol/mol), body weight
loss$5% and$10%, and composites of
HbA1c ,7.0% (53 mmol/mol) without
hypoglycemia (treatment-emergent se-
vere [defined according to the American
DiabetesAssociation (ADA) classification]
or blood glucose–confirmed [,3.1mmol/L
(56 mg/dL)]) symptomatic hypoglycemia
and without body weight gain, and
HbA1c reduction $1.0% (10.9 mmol/mol)
and body weight loss$3%. Changes from
baseline to weeks 26 and 52 in the fol-
lowing patient-reported outcomes
were also assessed: Short Form (SF)
36v2 Health Survey (Acute Version), Im-
pact of Weight on Quality of Life-Lite
Clinical Trial Version (IWQOL-Lite-
CT), and the Diabetes Treatment Sat-
isfaction Questionnaires (DTSQs).
Safety end points included the number
of treatment-emergent adverse events
(AEs) during exposure to trial product,
the number of severe or blood glucose–
confirmed symptomatic hypoglycemic ep-
isodes (as defined above for the composite
end point) and whether a patient experi-
enced such episodes, and changes from
baseline in laboratory assessments and
vital signs.
Statistical Analysis
A sample size of 180 patients per treat-
ment arm was calculated to provide
90% power to jointly confirm HbA1c
superiority of oral semaglutide over pla-
cebo at all dose levels at week 26.
Efficacy analyses were based on all
randomized patients. The confirmation
of efficacy of oral semaglutide on change
in HbA1c and body weight, both from
baseline to week 26, was based on a
weighted Bonferroni closed-testing strat-
egy (15) (outlined in Supplementary
Appendix 5) to control the overall type
I error for the hypotheses evaluated by
the treatment policy estimand.
The treatment policy estimand was
estimated by a pattern mixture model
using multiple imputation to handle
missing week 26 data for both confirma-
tory end points. Data collected at week
26 from all randomized patients irrespec-
tive of premature discontinuation of trial
product or initiation of rescue medica-
tion were included in the statistical anal-
ysis. Imputation was done within groups
defined by trial product and treatment
status at week 26. Both the imputation
and the analysis were based on ANCOVA
models. The results were combined by
use of Rubin’s rule (16).
The trial product estimand was esti-
mated by a mixed model for repeated
measurements that used data collected
prior to premature trial product discon-
tinuation or initiation of rescue medica-
tion from all randomized patients.
Safety end points were assessed using
the safety analysis set (all randomized
patients exposed to one or more doses
of trial product) and evaluated both on
treatment (i.e.,while receiving trial prod-
uct regardless of rescue medication use)
and in trial (i.e., while in the trial regard-
less of trial product discontinuation or
rescue medication use).
All statistical analyses were performed
using SAS version 9.4M2. Further details
can be found in Supplementary Appendix 5.
RESULTS
Patients
Of the 1,038 patients screened, 731
were randomized (oral semaglutide 3
mg, N 5 184; 7 mg, N 5 182; 14 mg,
N5181;placebo,N5184)and included in
the efficacy analyses (Supplementary Fig.
2). All patients, except one (oral semaglu-
tide 7 mg), were exposed to trial product
and included in the safety analysis set.
Demographics and baseline disease char-
acteristics are presented in Supplementary
Table 2.Overall, 395 (54.0%) patientswere
male, 376 (51.4%)werewhite, 263 (36.0%)
were Asian, and 49 (6.7%) were black or
African American. Mean age was 61 years,
mean HbA1c was 8.2% (66 mmol/mol),
mean body weight was 85.9 kg, and mean
diabetes duration was 15.0 years.
Overall, 697 (95.3%) patients com-
pleted the trial, and trial product was
discontinued prematurely by 24 (13.0%),
34 (18.7%), 37 (20.4%), and 22 (12.0%)
patients for oral semaglutide 3, 7, and
14 mg and placebo, respectively. By week
26, 5 (2.7%), 2 (1.1%), 4 (2.2%), and
9 (4.9%) patients, and by week 52,
54 (29.3%), 33 (18.1%), 31 (17.1%),
and 67 (36.4%) patients, had initiated
rescue medication for oral semaglutide 3,
7, and 14 mg and placebo, respectively
(Supplementary Table 3). The increased
use of rescue medication fromweek 26 to
52 (in most cases, a .20% increase in
total daily insulin dosage) reflects that
insulin was freely adjustable during
weeks 26–52 to reach an HbA1c ,7.0%.
Background metformin was used by
491 (67.2%) patients. The total number
of patients on each insulin regimen at
screening was 306 (41.9%), 284 (38.9%),
and 129 (17.6%) for basal, basal-bolus,
and premixed, respectively (Supplementary
Table 2). Twelve patients were recorded
to be on insulin regimens not defined in
the protocol: five were on regimens con-
sidered equivalent to those in the protocol
and continued in the trial, and seven were
randomized in error. Of these seven pa-
tients, one was never exposed to trial
product, and treatment was discontinued
for the remaining six upon discovery. For
clinical reporting, these patients were
assigned to the insulin regimen as orig-
inally assessed by the investigator.
At baseline, the overall mean (SD) total
daily insulin dosagewas 58 units (57 units).
The mean total daily insulin dosage at
baseline was slightly greater in the oral
semaglutide 3- and 7-mg arms than in
the 14-mg and placebo arms (61 and
63 units vs. 53 and 55 units, respectively)
(Supplementary Table 2). A 20% reduction
in total daily insulin dosage was recom-
mended when initiating trial product. The
majority ofpatients (75.3% [n5546]) had
their insulin dosage reduced by 15–25%.
For the remaining patients, the total daily
insulin dosage was reduced by,15% for
8.4% (n5 61), by.25% for 3.4% (n5 25),
and was unchanged for 12.4% (n 5 90).
There was no clear association between
HbA1c at screening and initial insulin
dosage reduction.
Glycemic Control
For the treatment policy estimand, the
estimated mean changes from base-
line in HbA1c at week 26 were –0.6%
(–6 mmol/mol), –0.9% (–10 mmol/mol),
–1.3% (–14 mmol/mol), and –0.1%
(–1 mmol/mol) for oral semaglutide
3, 7, and 14 mg and placebo, re-
spectively. Compared with placebo,
HbA1c reductions were superior for
all doses of oral semaglutide, with esti-
mated treatment differences (ETDs) of
–0.5% (95% CI –0.7, –0.3) (–5 mmol/mol
[–8, –3]; P , 0.0001), –0.9% (–1.1, –0.7)
(–10 mmol/mol [–12, –7]; P , 0.0001),
and –1.2% (–1.4, –1.0) (–13 mmol/mol
[–15, –11]; P , 0.0001) for the 3-, 7-,
and 14-mg doses, respectively (Fig. 1).
Sensitivity analyses were consistent with
these findings (Supplementary Table 4
and Supplementary Fig. 3). In addition,
there were statistically significantly greater
HbA1c reductions from baseline for all oral
semaglutide doses versus placebo at week
26 for the trial product estimand and at
week 52 for both estimands (Fig. 1). Fur-
thermore, the observed proportions of
patients achieving HbA1c ,7.0% (53
mmol/mol) and #6.5% (48 mmol/mol)
were greater with oral semaglutide com-
pared with placebo. The odds of achiev-
ing these targets were statistically
significantly greater with oral sema-
glutide than with placebo (both esti-
mands) (Table 1 and Supplementary
Table 5).
At week 26, the total daily insulin
dosage was reduced from baseline in
all treatment arms (Fig. 1). By week 52,
total daily insulin was reduced from base-
line with oral semaglutide 7 and 14 mg
and increasedwithoral semaglutide3mg
and placebo. These changes from base-
line were statistically significantly differ-
ent with oral semaglutide versus placebo
at weeks 26 and 52, except for the 3-mg
dose at week 26 for the treatment pol-
icy estimand. As previously mentioned,
many patients (mainly those on oral sema-
glutide 3 mg and placebo) increased their
total daily insulin dosage from baseline
by .20% during the freely adjustable
insulin treatment period (weeks 26–52)
(Supplementary Table 3). As this was
consideredrescuemedication, thisaffected
the results for this end point for the trial
product estimand, where only data prior
to initiation of rescue medication were
used when estimating the results (Fig. 1).
Changes from baseline in FPG (Fig. 1)
and 7-point SMBG means (Table 1) were
statistically significantly greater with oral
semaglutide than placebo at weeks
26 (except for FPG with 3 mg for the
treatment policy estimand) and 52 for
both estimands.
Body Weight
For the treatment policy estimand, the
estimated mean body weight changes
from baseline at week 26 were –1.4, –2.4,
–3.7, and –0.4 kg for oral semaglutide 3,
7, and 14 mg and placebo, respectively.
Compared with placebo, these body
weight reductions were superior for all
doses of oral semaglutide, with an ETD
of –0.9 kg (95%CI –1.8, –0.0;P50.0392),
–2.0 kg (–3.0, –1.0; P 5 0.0001), and
–3.3 kg (–4.2, –2.3; P , 0.0001) for the
3-, 7-, and 14-mg doses, respectively
(Fig. 2). Sensitivity analyseswereconsistent
with these findings (Supplementary Table 4
and Supplementary Fig. 3). There were
statistically significantly greater reductions
in body weight from baseline with all oral
semaglutide doses compared with placebo
for thetrialproductestimandatweek26and
for both estimands at week 52 (Fig. 2 and
Supplementary Table 5). Furthermore, the
observed proportions of patients achiev-
ing body weight loss $5% were greater
with oral semaglutide than with placebo.
The odds of achieving this outcome were
statistically significantly greater with oral
semaglutide than with placebo (both
estimands) (Fig. 2).
All oral semaglutidedoses reducedBMI
statistically significantly versus placebo
at weeks 26 and 52 (both estimands)
(SupplementaryTable5).Results forother
body weight–related end points are pre-
sented in Supplementary Table 5.
Other Outcomes
The observed proportions of patients
achieving HbA1c ,7.0% (53 mmol/mol)
without hypoglycemia and without body
weight gain were greater, and the odds
of achieving the outcome statistically
significantly greater,withoral semaglutide
compared with placebo (both esti-
mands) (Table 1). Oral semaglutide treat-
ment tended to improve the fasting lipid
profile from baseline. Reductions in total
cholesterolwere statistically significantly
greater with all oral semaglutide doses
compared with placebo for both esti-
mands at weeks 26 and 52, except for
the 3-mg dose at week 52 for the trial
product estimand (Supplementary Table
5). Results for the patient-reported out-
comes are presented in Supplementary
Results 1 and Supplementary Figs. 4–6
and for the other supportive secondary
end points in Supplementary Table 5.
Safety
Comparable proportions of patients ex-
perienced at least one AE while on treat-
ment (Table 2). Gastrointestinal disorders
occurred most frequently in the oral
semaglutide 7- and 14-mg arms (3 mg,
39.1% [n 5 72]; 7 mg, 44.8% [n 5 81];
14 mg, 50.3% [n 5 91]), whereas infec-
tions and infestations were most common
in the oral semaglutide 3-mg (39.7% [n5
73]) and placebo (43.5% [n5 80]) arms.
The most frequently reported AEs were
nausea with oral semaglutide (dose-
dependently affecting 11.4–23.2% [n 5
21–42] of patients) and nasopharyngitis
with placebo (14.7% [n5 27] of patients)
(Table 2). Of the nausea events, the
majority were of mild or moderate severity
andofshortduration(SupplementaryFig.7).
Serious AEs were reported by 13.6%
(n5 25), 10.5% (n5 19), 6.6% (n5 12),
and 9.2% (n5 17) of patients in the oral
semaglutide 3-, 7-, and 14-mg and pla-
cebo arms, respectively (Table 2). Trial
product was prematurely discontinued
because of AEs by 7.1% (n 5 13), 8.8%
(n516), 13.3% (n524), and2.7% (n55)
of patients for oral semaglutide 3, 7,
and 14 mg and placebo, respectively,
with gastrointestinal disorders being the
most frequent cause (Supplementary
Table 6).
There was one pregnancy during the
trial in a patient exposed to trial product
(oral semaglutide 7 mg); treatment was
discontinued, and the patient elected to
have a termination.
Very few patients experienced severe
hypoglycemic episodes (Table 2). The
proportions of patients with a severe
or blood glucose–confirmed symptom-
atic hypoglycemic episode were similar
between patients receiving oral semaglu-
tide and placebo (3 mg, 28.3% [n 5 52];
Figure 1—Glycemic control–related efficacy end points. A: Observed absolute HbA1c over time. ▼, placebo; ▲, oral semaglutide 3 mg; ◆, oral
semaglutide 7 mg; ▪, oral semaglutide 14 mg. B: Estimated changes from baseline in HbA1c. C: Estimated changes from baseline in FPG. D: Estimated
changes from baseline in total daily insulin dosage. Treatment policy estimand: ANCOVA for continuous end points and logistic regression for binary end
points, using data irrespective of discontinuation of trial product or initiation of rescue medication. Missing values were imputed by a pattern mixture model
using multiple imputation. Pattern was defined by randomized trial product and treatment status. Trial product estimand: mixed model for repeated
measurements for continuous end points and logistic regression for binary end points. Data collected after discontinuation of trial product or initiation
of rescue medication were excluded. For binary end points, missing values were imputed from patients randomized to the same trial product using
sequential multiple imputation. *Statistically significant ETD versus placebo in favor of oral semaglutide. P values are unadjusted two-sided P values
for the test of no difference.
7 mg, 26.0% [n 5 47]; 14 mg, 26.5%
[n5 48]; placebo, 29.3% [n5 54]) (Table
2). Across all treatment arms, the greatest
number of hypoglycemic episodes oc-
curred in patients on basal-bolus insulin.
Comparable proportions of patients
experienced diabetic retinopathy–
related AEs (Supplementary Table 7), all
of which were mild or moderate in
severity. Retinopathy events were iden-
tified during routine examination for
40 patients (10 per treatment arm),
and 8 patients required treatment.
The prevalence of external event adju-
dication committee (EAC)–confirmed
cardiovascular events and acute kidney
injury events during the trial was low
and similar across treatment arms
(Supplementary Table 8). Few patients
had EAC-confirmed malignant neoplasms,
and there were no EAC-confirmed events
of acute pancreatitis.
There were three deaths during the trial,
all of which occurred on treatment with
oral semaglutide 14 mg (Supplementary
Table 8). Of these patients, none reported
severe or blood glucose–confirmed symp-
tomatic hypoglycemic episodes during the
trial. The EAC-confirmed cause of death
was infection for one patient; cause of
death was undetermined for the remain-
ing two patients because their medical
records were unavailable.
Compared with placebo, pulse rate
increased for the oral semaglutide
arms, with ETD of 2–4 beats/min at week
26 (all groups P , 0.05) and 1–2 beats/
min at week 52 (P , 0.05 for oral
semaglutide 14 mg only) while on treat-
ment. There were no clinically relevant
changes in laboratory safety parameters
or other vital signs reported in any pa-
tients (Supplementary Table 9).
CONCLUSIONS
In this trial, oral semaglutide 3, 7, and
14 mg provided dose-dependent, statis-
tically significant reductions in HbA1c and
body weight compared with placebo over
52 weeks in patients with type 2 diabetes
inadequately controlledwith insulinwith
orwithoutmetformin. Furthermore, oral
semaglutide treatment enabled up to
54.2% of patients to achieve HbA1c
,7.0% (53 mmol/mol) at week 52 (treat-
ment policy estimand). Better glycemic
control was achieved with oral semaglutide
7 and 14 mg compared with placebo at
weeks 26 and 52, despite lower total daily
insulin dosages relative to baseline. These
findings support the addition of GLP-1RAs
as an effective treatment intensification
strategy for patients who are unable to
reach, or maintain, HbA1c targets with
insulin alone (17), as recommended in
current treatment guidelines (3).
TheHbA1c and bodyweight reductions
with oral semaglutide in this trial were
similar to those reported in other
PIONEER trials (13,18–20). Typical of a
population on established insulin therapy,
patients in PIONEER 8 were older and had
Table 1—Key supportive secondary end points
Treatment policy estimand Trial product estimand
Oral semaglutide Oral semaglutide
3 mg 7 mg 14 mg Placebo 3 mg 7 mg 14 mg Placebo
Patients, n 184 182 181 184 184 182 181 184
HbA1c ,7.0%
Week 26
Patients meeting end point, n (%) 50 (28.4) 74 (42.5) 101 (58.4) 12 (6.8) 50 (30.9) 70 (44.6) 96 (65.8) 11 (6.8)
EOR vs. placebo 5.61 12.37 22.52 d 6.35 14.21 31.84 d
95% CI 2.77, 11.37 6.12, 25.00 11.14, 45.51 d 3.10, 13.00 6.89, 29.29 15.35, 66.04 d
P value ,0.0001 ,0.0001 ,0.0001 d ,0.0001 ,0.0001 ,0.0001 d
Week 52
Patients meeting end point, n (%) 50 (28.9) 67 (39.6) 91 (54.2) 16 (9.3) 37 (35.6) 53 (46.9) 72 (64.3) 10 (10.1)
EOR vs. placebo 4.02 7.21 12.96 d 4.59 7.90 16.00 d
95% CI 2.13, 7.58 3.84, 13.54 6.91, 24.32 d 2.22, 9.50 3.82, 16.36 7.77, 32.91 d
P value ,0.0001 ,0.0001 ,0.0001 d ,0.0001 ,0.0001 ,0.0001 d
Seven-point SMBG* (mmol/L)
Week 26
Estimated mean 8.9 8.4 8.1 9.7 8.8 8.2 7.7 9.7
Estimated change from baseline 21.1 21.7 21.9 20.3 21.2 21.7 22.3 20.3
ETD vs. placebo 20.8 21.4 21.7 d 20.9 21.5 22.1 d
95% CI –1.3, –0.3 –1.8, –0.9 –2.1, –1.2 d –1.4, –0.5 –1.9, –1.0 –2.5, –1.6 d
P value 0.0006 ,0.0001 ,0.0001 d ,0.0001 ,0.0001 ,0.0001 d
Week 52
Estimated mean 8.5 8.4 8.0 9.2 8.5 8.3 7.9 9.3
Estimated change from baseline 21.5 21.6 22.0 20.8 21.5 21.7 22.1 20.7
ETD vs. placebo 20.6 20.8 21.1 d 20.8 21.0 21.4 d
95% CI –1.2, –0.1 –1.3, –0.3 –1.7, –0.6 d –1.3, –0.3 –1.5, –0.5 –1.8, –0.9 d
P value 0.0161 0.0035 ,0.0001 d 0.0012 ,0.0001 ,0.0001 d
Proportions are observed proportions of patients with nonmissing information. P values are unadjusted two-sided P values for the test of no
difference. Treatment policy estimand: ANCOVA for continuous end points and logistic regression for binary end points using data irrespective
of discontinuation of trial product or initiation of rescuemedication. Missing values were imputed by a patternmixture model using multiple imputation.
Pattern was defined by randomized trial product and treatment status. Trial product estimand: mixedmodel for repeated measurements for continuous
end points and logistic regression for binary end points. Data collected after discontinuation of trial product or initiation of rescue medication were
excluded. For binary end points, missing values were imputed from patients randomized to the same trial product using sequential multiple imputation.
EOR, estimated odds ratio. *SMBG is reported as plasma-equivalent values of capillary whole-blood glucose.
Figure 2—Body weight–related efficacy end points. A: Observed changes from baseline in body weight over time. ▼, placebo; ▲, oral semaglutide
3 mg;◆, oral semaglutide 7 mg; ▪, oral semaglutide 14 mg. B: Estimated changes from baseline in body weight. C: Observed proportions of patients
achieving $5% weight loss. D: Observed proportions of patients achieving HbA1c ,7.0% without hypoglycemia and without body weight gain.
Treatment policy estimand: ANCOVA for continuous end points and logistic regression for binary end points, using data irrespective of discontinuation
of trial product or initiation of rescue medication. Missing values were imputed by a pattern mixture model using multiple imputation. Pattern was
defined by randomized trial product and treatment status. Trial product estimand: mixed model for repeated measurements for continuous end
points and logistic regression for binary end points. Data collected after discontinuation of trial product or initiation of rescue medication were
excluded. For binary end points, missing values were imputed from patients randomized to the same trial product using sequential multiple
imputation. *Statistically significant ETD or estimated odds ratio (EOR) versus placebo in favor of oral semaglutide. P values are unadjusted two-sided
P values for the test of no difference. †Severe or blood glucose–confirmed (,3.1 mmol/L [,56 mg/dL]) symptomatic hypoglycemic episode.
more advanced disease than those in
these other trials (13,18–20). However,
the similarities in the results, regardless of
population differences, highlight the con-
sistency of effect of oral semaglutide
across the spectrum of care. Furthermore,
these clinical benefits are consistent
with results achieved with subcutane-
ous semaglutide in patients treated
with insulin (6), suggesting that these
individuals could benefit from semaglu-
tide regardless of administration route.
Oral semaglutide may help to over-
come some of the side effects associated
with insulin use that contribute to thera-
peutic inertia in the initiation or intensifi-
cationofan insulin regimen(21,22), suchas
weight gain (23). When added to insulin in
the present trial, oral semaglutide resulted
in significant body weight reductions ver-
sus placebo. Furthermore, the total daily
insulin dosage was significantly reduced
from baseline with oral semaglutide 7 and
14 mg versus placebo at weeks 26 and
52, suggesting an insulin-sparing effect at
these doses.
Insulin use is also associated with an
increased risk of hypoglycemia (24,25),
which could be overcome by adding a
GLP-1RA. Indeed, in a prior trial, the fixed
combination of liraglutide and insulin
degludec improved glycemic control
compared with the equivalent dose of
insulin alone, without increasing the
hypoglycemia risk (26). Similarly, in
our trial, despite the better glycemic
control achieved with oral semaglutide,
the proportions of patients with at least
one severe or blood glucose–confirmed
symptomatic hypoglycemic episode
were similar across treatment arms. For
all treatment arms, most of these episodes
occurred in patients on basal-bolus insulin.
This would be expected from a regimen
with a prandial component, and an associ-
ation between hypoglycemia and bolus in-
sulin has previously been reported (27,28).
Hypoglycemia is also associated with
cardiovascular-related morbidity and
mortality (29). In this trial, no associa-
tion between severe or blood glucose–
confirmed symptomatic hypoglycemic
episodes and cardiovascular events was
observed.
Consistent with other semaglutide tri-
als (6,13,19,30), no unexpected safety
issues were identified. Gastrointestinal
Table 2—On-treatment AEs and hypoglycemic episodes
Oral semaglutide
3 mg (n 5 184) 7 mg (n 5 181) 14 mg (n 5 181) Placebo (n 5 184)
AEs n (%) R n (%) R n (%) R n (%) R
Any AE 137 (74.5) 336 142 (78.5) 315 151 (83.4) 344 139 (75.5) 245
Most frequent AEs affecting $5% of patients in any
treatment arm (by MedDRA preferred term)
Nausea 21 (11.4) 12 30 (16.6) 19 42 (23.2) 37 13 (7.1) 10
Diarrhea 16 (8.7) 10 22 (12.2) 15 27 (14.9) 24 11 (6.0) 8
Decreased appetite 8 (4.3) 4 18 (9.9) 11 23 (12.7) 14 2 (1.1) 1
Vomiting 11 (6.0) 8 14 (7.7) 10 18 (9.9) 18 7 (3.8) 4
Nasopharyngitis 27 (14.7) 23 21 (11.6) 18 18 (9.9) 17 27 (14.7) 18
Upper respiratory tract infection 8 (4.3) 6 6 (3.3) 5 13 (7.2) 8 13 (7.1) 9
Constipation 8 (4.3) 4 15 (8.3) 9 12 (6.6) 8 5 (2.7) 3
Abdominal discomfort 7 (3.8) 4 11 (6.1) 7 10 (5.5) 6 3 (1.6) 2
Urinary tract infection 6 (3.3) 5 5 (2.8) 3 10 (5.5) 6 7 (3.8) 6
Hypertension 3 (1.6) 2 4 (2.2) 2 1 (0.6) 1 11 (6.0) 6
Serious AEs 25 (13.6) 23 19 (10.5) 15 12 (6.6) 14 17 (9.2) 13
AEs leading to premature trial product discontinuation 13 (7.1) 16 16 (8.8) 17 24 (13.3) 29 5 (2.7) 3
AEs leading to premature trial product discontinuation
affecting $3% of patients in any treatment arm (by
MedDRA system organ class)
Gastrointestinal disorders 9 (4.9) 8 12 (6.6) 13 19 (10.5) 19 1 (0.5) 1
Deaths 0 0 0 0 3 (1.7) 2 0 0
Hypoglycemic episodes by classification and
insulin regimen* n/N (%) R n/N (%) R n/N (%) R n/N (%) R
Severe or blood glucose–confirmed symptomatic†‡ 52 (28.3) 105 47 (26.0) 102 48 (26.5) 86 54 (29.3) 82
Basal insulin 8/77 (10.4) 25 12/76 (15.8) 52 10/76 (13.2) 27 16/80 (20.0) 30
Basal-bolus insulin 36/71 (50.7) 206 29/73 (39.7) 168 31/70 (44.3) 155 27/72 (37.5) 155
Premixed insulin 8/36 (22.2) 92 6/32 (18.8) 62 7/35 (20.0) 76 11/32 (34.4) 52
Severe‡ 5 (2.7) 3 1 (0.6) 1 2 (1.1) 1 1 (0.5) 1
Basal insulin 0 0 0 0 0 0 0 0
Basal-bolus insulin 4/71 (5.6) 6 1/73 (1.4) 1 1/70 (1.4) 1 0 0
Premixed insulin 1/36 (2.8) 3 0 0 1/35 (2.9) 4 1/32 (3.1) 3
Data are number and proportion of patients with at least one event or number and proportion of patients experiencing at least one hypoglycemic
episodeover number of patients on each insulin regimen,where applicable. On treatment: the period inwhich the patientwas considered treatedwith
trial product. MedDRA, Medical Dictionary for Regulatory Activities (version 20.1); R, observed rate of episodes per 100 years of exposure.
*Hypoglycemic episodes were reported on a separate form from AEs. †Severe hypoglycemia was defined according to the ADA classification (requires
assistance of another person to actively administer carbohydrate, glucagon, or other corrective action). ‡Blood glucose confirmation of symptomatic
hypoglycemia was based on a blood glucose value ,3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycemia.
disorders, specifically nausea, were the
most frequentAEswithoral semaglutide,
which is consistent with other GLP-1RAs,
and nausea is a known class effect of
these agents (1). A dose escalation was
used to help to mitigate the occurrence
and severity of nausea, and the nausea
events observed were mild or moderate
and of short duration.
A strength of this trial was the inclusion
of the consecutive insulin dosing stages
(capped at baseline levels, then fully
adjustable) during the treatment period.
This allowed both the glucose-lowering
effect of oral semaglutide to be deter-
mined in a controlled setting and data to
beobtained longer term ina settingmore
reflective of clinical practice. However,
the diversity of insulin types and regi-
mens could have limited assessment of
the interaction of oral semaglutide with
specific regimens. In addition, titration of
insulin dosage was performed at the
discretion of individual investigators
and was not enforced. While this was in
linewith the aim of the trial, it resulted in
HbA1c at week 52 being similar to base-
line levels in patients receiving placebo.
Had the insulin titration after week
26 been enforced, the comparison be-
tween oral semaglutide and placebo with
regard to frequency of hypoglycemia and
changes from baseline in insulin dosage
could have been further strengthened.
Furthermore, while the use of a placebo
control allowed the evaluation of treat-
ment effect, using an active comparator
instead could have provided additional
insight into the relative risks or benefits
of oral semaglutide comparedwith other
available approaches.
In summary, when added to insulin in
the setting of inadequately controlled
type 2 diabetes, oral semaglutide was
superior to placebo at improving glycemic
control and reducing body weight over
26 weeks, with significant differences also
seen at 52weeks, andwith no increase in
the risk of hypoglycemia. Further-
more, the overall safety profile was
consistent with that of other GLP-1RAs.
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